ReviewTherapeutic advances in hematology2021

Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma.

Larysa Sanchez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.